医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

GN MEDI Antibacterial Spray Launched to End COVID-19 Crisis and Solve the Shortage of Masks

2020年03月27日 PM09:00
このエントリーをはてなブックマークに追加


 

SEOUL, South Korea

Ventex launched GN MEDI 99.9% antibacterial spray which is an eco-friendly and odorless product containing harmless minerals for sterilization and disinfection.

The product is developed by Ventex, a technology company that received IR52 Jang Young-shil Awards hosted by MSIT five times. Ventex received the awards in 2019, thanks to the antibacterial spray that featured the world’s first ‘coating technique with antibacterial mineral’.

GN MEDI 99.9% antibacterial spray eliminates 99.9 percent of pneumococcus, colon bacillus, and staphylococcus aureus. And Korea Testing & Research Institute checked that it sterilized 99.99 percent of Influenza A virus that is the same RNA virus family as COVID-19.

Nationally Authorized Testing- Inspection and Research Institute, KOTITI checked that the masks’ filters worked fine after spraying the antibacterial spray on KF94 masks. They checked filters’ functions under criteria, passing the amount of paraffin oil per minute following the test method of KF masks. It was widely known that KF94 masks usually prevent ninety-four percent.

When KOTITI tested pneumococcus after seventy-two hours from spraying the antibacterial spray on the mask, the mask had maintained 99.9 percent of excellent antibacterial function. The spray also eliminates the offensive smell.

Gyeongchan Go, President of Ventex said, “GN MEDI 99.9% antibacterial spray maintains the antibacterial effect for a long time compared to highly volatile ethanol and has an excellent safety unlike chlorine-releasing products causing cancers. Now you can use our spray that passed the skin irritation test for clothing and textile products as well as doorknobs, hand straps on the metro, and elevator buttons.”

The antibacterial spray is also used for sterilization, disinfection, and deodorization and acknowledged by KATRI that they fit for a stability standard of risk-concerned products. The safety test result will come out from U.S. Food and Drug Administration (FDA) during this month.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200327005109/en/

CONTACT

Ventex

Boram Jung

+82-70-4827-4877

bbo0026@gncos.co.kr

同じカテゴリーの記事 

  • 卫材启用Medidata Clinical Data Studio推进临床试验效率和患者体验的革新
  • Fujirebio推出研究专用全自动Lumipulse®G GFAP检测试剂盒并进一步强化该公司的神经病学产品阵容
  • Fujirebio Launches the Fully Automated Lumipulse® G GFAP Assay for Research Use Only and Further Strengthens its Neuro Test Menu
  • Pearl、歯科AIで史上最大5,800万ドルの資金調達ラウンドを実施
  • FIGS Announces Date of Second Quarter 2024 Earnings Release, Conference Call and Webcast